Letermovir to reduce immune activation in older adults with HIV
Treatments studied
Part of Infections clinical trials.
This study tests if a drug called Letermovir can help reduce immune activation in people with well-controlled HIV who are over 50. You may be eligible if you've had a low CD4 count in the past and carry CMV (a common virus that can reactivate).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 50 years old or older
- Your HIV must be well-controlled (viral load under 50) for at least a year
- Your lowest-ever CD4 count must have been 200 or lower
- You must have tested positive for CMV in the last year
- You cannot have certain bowel conditions like ulcerative colitis or Crohn's disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a combination approach, including a drug called nicotinamide (a form of vitamin B3) and other strategies, can reduce the hidden HIV reservoir enough to allow a temporary pause in antiretroviral therapy without the virus rebounding. It is for people who have well-controlled HIV and strong immune systems.
This trial tests if a drug called letermovir can safely prevent CMV (a common virus) from reactivating after you receive CAR T-cell therapy (Axi-cel). It may help reduce infections and side effects.
This trial studies whether letermovir can help prevent CMV (a common virus after transplant) from coming back after you’ve already been treated. If you qualify, you may be offered letermovir as “secondary prevention” and followed for about 6 months.
This study tests a drug called letermovir to prevent CMV infection after a kidney or liver transplant. It is for adults at moderate risk of CMV and may help keep you healthy after surgery.
This trial tests whether the medicine letermovir can prevent a common virus (CMV) from coming back after an allogeneic stem cell transplant in children. It may help lower the risk of CMV infection during the vulnerable period right after transplant.
This trial tests if the drug letermovir can prevent a common virus (CMV) in children who have certain blood disorders and are getting a stem cell transplant. It aims to keep you safer during recovery.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.